Physician profile
George Sarka
NPI 1083835433
$6,659.83
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $4,938 · 2021: $110 · 2022: $252 · 2023: $237 · 2024: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,760.72 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $477.18 | 2022-2024 | Austedo Xr, Ajovy |
| Genentech USA, INC. | $270.55 | 2019 | |
| Akcea Therapeutics, INC. | $188.00 | 2019-2020 | |
| Insightec,INC | $141.34 | 2024 | Exablate |
| Genzyme Corporation | $125.01 | 2024 | |
| Strongbridge US INC. | $125.00 | 2019 | |
| Eisai INC. | $123.88 | 2024 | |
| Alexion Pharmaceuticals, INC. | $108.85 | 2020 | |
| Acorda Therapeutics, INC | $92.59 | 2022 | |
| Mdd US Operations, LLC | $83.30 | 2019 | |
| Sk Life Science, INC. | $60.03 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $50.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $39.43 | 2022 | |
| Abbvie INC. | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sarka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.